For Healthcare Professionals

A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy

clipboard-pencil

About the study

This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in subjects with hematologic malignancies who have failed standard treatment.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. Histologically/cytologically confirmed hematologic malignancy who failed the standard treatment
  2. At least one evaluable lesion
  3. Male or female 18 to 75 years old
  4. Eastern Cooperative Oncology Group Performance Status Performance Status (ECOG PS) 0-2
  5. Must have adequate organ function

EXCLUSION CRITERIA

Exclusion Criteria:

  1. Previous exposure to any anti-CD47 monoclonal antibody, SIRPα antibody, or CD47/SIRPα recombinant protein
  2. Previous exposure to chimeric antigen receptor T cell immunotherapy (CAR-T)
  3. Subjects participating in another interventional clinical study, except for: observational (non-interventional) clinical studies or survival follow-up phase of interventional studies
  4. Use of anticoagulants and/or aspirin, or other non-steroidal anti-inflammatory drugs within 2 weeks prior to study start
  5. A history of blood transfusion within 2 weeks prior to study start
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Hematologic Malignancy

Age (in years)

18 - 75

Phase

Phase 1

Participants needed

230

Est. Completion Date

Apr 30, 2024

Treatment type

Interventional


Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

ClinicalTrials.gov identifier

NCT04795128

Study number

CIBI322A103

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.